All Press Releases
PILA PHARMA: INVITATION TO LIVE H1 REPORT INTERVIEW AND Q&A
Malmö, 21 August 2025 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition for treatment of obesity and diabetes, invites shareholders, investors and other stakeholders with interest in the space, to a live online interview and Q&A. CEO Gustav H. Gram will present online at 13:30 CEST on August 27, 2025, in connection…
PILA PHARMA ANNOUNCES THE COMPLETION OF REGISTRATION OF SHARES IN THE RIGHTS ISSUE AND ITS ASSOCIATED DIRECTED ISSUES, MARKING THE END OF THE RIGHTS ISSUE PROCESS
Malmö, 21 August 2025 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announced on 23 July 2025 that the rights issue of units that was resolved by the board of directors, subject to the annual general meeting's authorization held on 29 April 2024 (the "Authorization"), on 19 June (the "Rights Issue") was completed. In connection to the Rights Issue,…
PILA PHARMA announces updated dates for last day of trading with paid subscribed units and first day of trading in new shares
Malmö, 31 July 2025 PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") announces that the last day of trading in paid subscribed units (Sw. BTU) in connection with the Company's rights issue of units which the Board of Directors resolved on 19 June 2025, with the authorization from the annual general meeting held 29 April 2025 (the "Rights Issue"),…